UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): February 17, 2026~~1934

     Date of Report (Date of earliest event reported): February 26, 2026

    

DISC MEDICINE, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39438	85-1612845
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

321 Arsenal Street Suite 101
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 617 674-9274

    

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol~~(s)~~		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		IRON		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102 RegulationResults FDof DisclosureOperations and Financial Condition.

On February 1726, 2026, Disc Medicine, Inc. ~~(the "Company") will host a previously-~~announced ~~conference~~its ~~call~~financial atresults ~~8:00~~for ~~AM ET to discuss~~ the ~~Complete~~fourth ~~Response~~quarter ~~Letter issued by the U.S. Food~~ and ~~Drug~~fiscal ~~Administration~~year onended ~~February~~December 1331, ~~2026~~2025 ~~with~~and ~~respect~~provided ~~to the Company's New Drug Application for bitopertin as~~ a ~~treatment~~corporate ~~for patients with erythropoietic protoporphyria~~update. ~~An archived webcast will be available following the call for 30 days on the Events & Presentations section of the Company’s website.~~ A copy of the ~~slide~~press ~~presentation~~release toin beconnection ~~presented~~with ~~during~~ the ~~conference~~announcement ~~call~~ is ~~attached~~being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information ~~contained~~ in this Item 72.0102 of this Current Report on Form 8-K, (including Exhibit 99.1, attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly ~~provided~~set forth by specific reference in such filing. ~~The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.~~

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Disc Medicine, Inc. ~~presentation,~~on ~~dated~~ February 26, 2026, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

~~SIGNATURES~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			DISC MEDICINE, INC.
Date:	February 1726, 2026	By:	/s/ John Quisel, J.D., Ph.D.
			Name: John Quisel, J.D., Ph.D.Title: Chief Executive Officer
			Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer

Filing Compare · Disc Medicine, Inc.